Table 2.
Clinical, laboratory, and procedural characteristics of prasugrel (n = 118)- and ticagrelor (n = 88)-treated patients without and with hyperuricemia
| Characteristics | Prasugrel | Ticagrelor | ||||
|---|---|---|---|---|---|---|
| No hyperuricemia (n = 98) | Hyperuricemia (n = 20) | p | No hyperuricemia (n = 66) | Hyperuricemia (n = 22) | p | |
| Demographics | ||||||
| Age, years | 56.1 (50.9–61.7) | 57 (37.8–70.6) | 0.82 | 56.8 (50–68.8) | 64.9 (58.8–73) | 0.05 |
| Male sex | 78 (79.6) | 19 (95) | 0.12 | 56 (84.8) | 12 (54.5) | 0.003 |
| BMI (kg/m2) | 27.8 (25.2–30.4) | 28.1 (24.1–32) | 0.65 | 26.8 (24.2–29.7) | 27 (25.7–30.7) | 0.43 |
| Medical history | ||||||
| Hypertension | 62 (63.3) | 15 (75) | 0.31 | 46 (69.7) | 16 (72.7) | 0.79 |
| Hyperlipidemia | 76 (77.6) | 16 (80) | 0.81 | 48 (72.2) | 18 (81.8) | 0.39 |
| Diabetes mellitus | 17 (17.4) | 7 (35) | 0.12 | 21 (31.8) | 6 (27.3) | 0.69 |
| Active smoking | 56 (57.1) | 13 (65) | 0.52 | 38 (57.6) | 9 (40.9) | 0.18 |
| Laboratory data | ||||||
| Hemoglobin (g/dL) | 13.9 (13.1–14.7) | 14 (13.3–15.4) | 0.46 | 14 (12.7–14.6) | 13.3 (11.9–14.6) | 0.4 |
| WBC (G/L) | 8.9 (7.9–10.2) | 9.8 (7.8–11.8) | 0.29 | 9.2 (6.6–10.5) | 9.5 (7.3–10.6) | 0.59 |
| Platelet count (G/L) | 224 (197–253) | 194 (172–219) | 0.01 | 223 (186–265) | 238 (215–269) | 0.15 |
| Serum creatinine (mg/dL) | 0.9 (0.8–1) | 1.1 (0.9–1.2) | <0.001 | 1 (0.8 − 1.1) | 1.2 (0.8–1.5) | 0.02 |
| hsCRP (mg/dL) | 1.2 (0.7–3.6) | 2 (0.5–6) | 0.63 | 1.1 (0.4–3.7) | 1.5 (1–3.5) | 0.36 |
| Medication | ||||||
| Aspirin | 98 (100) | 20 (100) | 1 | 66 (100) | 22 (100) | 1 |
| Allopurinol | 2 (2) | 2 (10) | 0.13 | 2 (3) | 1 (4.5) | 1 |
| Statin | 97 (99) | 20 (100) | 0.65 | 65 (98.5) | 22 (100) | 1 |
| ACE inhibitor/ARB | 94 (95.9) | 20 (100) | 1 | 64 (97) | 20 (90.9) | 0.26 |
| Beta blocker | 96 (98) | 18 (90) | 0.13 | 65 (98.5) | 21 (95.5) | 0.44 |
| PPI | 75 (76.5) | 14 (70) | 0.57 | 43 (65.2) | 17 (77.3) | 0.29 |
| CCB | 6 (6.1) | 4 (20) | 0.07 | 5 (7.6) | 5 (22.7) | 0.11 |
Continuous data are shown as median (interquartile range). Dichotomous data are shown as n (%).
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CCB calcium channel blocker, hsCRP high-sensitivity C-reactive protein, PPI proton pump inhibitor, WBC white blood cell count